Ad
related to: dabrafenib and trametinib overall survival- See Instructions for Use
Help your patients get started
with OJEMDA. Read this guidance.
- Read the Access Brochure
Learn about reimbursement support
and access for OJEMDA
- Contact a Rep
Learn why OJEMDA might be right
for your pediatric patients
- Sign Up for Updates
Sign up to stay informed
about the latest data
- See Instructions for Use
Search results
Results from the WOW.Com Content Network
The combination of dabrafenib and trametinib has shown significant increases in overall survival and has been approved by the FDA. Another similar combination is vemurafenib and cobimetinib. Immunotherapy is also starting to play an important role in anaplastic thyroid cancer management with several ongoing clinical trials demonstrating ...
Dabrafenib is indicated as a single agent for the treatment of people with unresectable or metastatic melanoma with BRAF V600E mutation. [2] Dabrafenib is indicated, in combination with trametinib, for BRAF V600E-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, and unresectable or metastatic solid tumors.
The combination of dabrafenib and trametinib was approved for NHS use for youngsters with brain tumours in April. However, Alexander has been accessing the medication privately at a cost of about ...
Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma [4] [5] and glioma. [ 6 ] [ 7 ] It is a MEK inhibitor drug with anti-cancer activity. [ 8 ]
For premium support please call: 800-290-4726 more ways to reach us
U0126 [1] [2] is the 'code' name for a compound associated with cancer treatment [3] and also in preventing ischemia and cellular oxidative stress. It also has likely utility in strokes and heart attacks. [4]
A phase III trial (vs dacarbazine) in patients with previously untreated metastatic melanoma showed an improved rates of overall and progression-free survival. [18] In June 2011, positive results were reported from the phase III BRIM3 BRAF-mutation melanoma study. [19] The BRIM3 trial reported good updated results in 2012. [20]
In October 2012 a study reported that combining Dabrafenib with a MEK inhibitor trametinib led to even better outcomes. Compared to Dabrafenib alone, progression-free survival was increased to 41% from 9%, and the median progression-free survival increased to 9.4 months versus 5.8 months. Some side effects were, however, increased in the ...
Ad
related to: dabrafenib and trametinib overall survival